Citadel Advisors’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.2M | Sell |
1,773,188
-181,284
| -9% | -$1.74M | ﹤0.01% | 2753 |
|
|
2025
Q4 | $22.8M | Buy |
1,954,472
+368,439
| +23% | +$3.58M | ﹤0.01% | 2194 |
|
|
2025
Q3 | $15.9M | Sell |
1,586,033
-656,143
| -29% | -$9.42M | ﹤0.01% | 2614 |
|
|
2025
Q2 | $39.1M | Buy |
2,242,176
+1,440,886
| +180% | +$20.8M | 0.01% | 1440 |
|
|
2025
Q1 | $10.1M | Sell |
801,290
-4,166
| -0.5% | -$50.1K | ﹤0.01% | 2849 |
|
|
2024
Q4 | $8.5M | Buy |
805,456
+552,957
| +219% | +$7.74M | ﹤0.01% | 3194 |
|
|
2024
Q3 | $3.66M | Buy |
252,499
+161,741
| +178% | +$1.92M | ﹤0.01% | 4456 |
|
|
2024
Q2 | $772K | Sell |
90,758
-21,307
| -19% | -$189K | ﹤0.01% | 7125 |
|
|
2024
Q1 | $1.15M | Buy |
112,065
+80,262
| +252% | +$598K | ﹤0.01% | 6653 |
|
|
2023
Q4 | $174K | Buy |
31,803
+20,265
| +176% | +$88.8K | ﹤0.01% | 10150 |
|
|
2023
Q3 | $43.6K | Sell |
11,538
-208,810
| -95% | -$1.37M | ﹤0.01% | 11907 |
|
|
2023
Q2 | $1.48M | Buy |
220,348
+175,572
| +392% | +$1.17M | ﹤0.01% | 5708 |
|
|
2023
Q1 | $291K | Buy |
44,776
+36,479
| +440% | +$280K | ﹤0.01% | 9435 |
|
|
2022
Q4 | $70.8K | Sell |
8,297
-89,173
| -91% | -$579K | ﹤0.01% | 11688 |
|
|
2022
Q3 | $515K | Sell |
97,470
-134,196
| -58% | -$661K | ﹤0.01% | 8394 |
|
|
2022
Q2 | $982K | Buy |
231,666
+36,510
| +19% | +$127K | ﹤0.01% | 7058 |
|
|
2022
Q1 | $685K | Buy |
195,156
+101,591
| +109% | +$442K | ﹤0.01% | 8629 |
|
|
2021
Q4 | $623K | Buy |
93,565
+19,073
| +26% | +$155K | ﹤0.01% | 9130 |
|
|
2021
Q3 | $743K | Buy |
74,492
+39,844
| +115% | +$983K | ﹤0.01% | 8904 |
|
|
2021
Q2 | $1.07M | Buy |
+34,648
| New | +$1.11M | ﹤0.01% | 8207 |
|
|
2021
Q1 | – | Sell |
-138,138
| Closed | -$6.4M | – | 13684 |
|
|
2020
Q4 | $6.4M | Buy |
+138,138
| New | +$4.61M | ﹤0.01% | 3263 |
|
Other funds holding SPRY
RCM
O
RCMNY
DM
SOCM
